Acumen Hypotension Prediction Index (HPI) Feature Software vs SignalHF
AI Verdict
Choose Acumen Hypotension Prediction Index (HPI) Feature Software if…
Choose Acumen Hypotension Prediction Index (HPI) Feature Software if your primary goal is real-time, proactive hemodynamic management in acute care settings like the OR or ICU. This tool is ideal for clinicians who need to anticipate and prevent hypotensive events up to 15 minutes before they occur, leveraging machine learning to guide immediate interventions and optimize patient stability during critical periods.
View Acumen Hypotension Prediction Index (HPI) Feature Software →Choose SignalHF if…
Choose SignalHF if your focus is on long-term, predictive risk assessment for heart failure patients with cardiac implantable electronic devices (CIEDs). This AI algorithm is best suited for cardiology practices and care teams aiming to identify patients at high risk of heart failure hospitalization within 30 days, enabling timely outpatient interventions and personalized care plans to prevent acute events.
View SignalHF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Acumen Hypotension Prediction Index (HPI) Feature Software | SignalHF |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Unknown | SaaS |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
SignalHFSignalHF (Tool B) offers a SaaS deployment and manufacturer-agnostic compatibility with various cardiac implantable electronic devices (CIEDs), providing a single, unified platform for diverse data sources. This simplifies IT infrastructure and workflow for clinicians managing patients with different device brands. While Acumen HPI (Tool A) offers intuitive screens and alerts, its integration into a proprietary monitoring platform (HemoSphere) may limit its broader applicability for institutions not already using that ecosystem.
Clinical Value
SignalHFBoth tools demonstrate strong clinical value with FDA clearance and supporting studies. Acumen HPI (Tool A) significantly reduces the incidence, duration, and severity of intraoperative hypotension, directly impacting acute surgical outcomes. SignalHF (Tool B), through its platform, shows a substantial 26% reduction in mortality and a 4% reduction in heart failure hospitalization length, offering a broader impact on long-term patient survival and reduced healthcare burden for chronic heart failure patients.
Pricing & Value
TieBoth tools explicitly state that their pricing information is not publicly available and requires direct contact with the vendor. Without any transparent pricing details or comparative cost-effectiveness analyses, it is impossible to assess which tool offers better value for money.
Enterprise Readiness
SignalHFSignalHF (Tool B) demonstrates stronger enterprise readiness due to its SaaS deployment, manufacturer-agnostic compatibility with all major CIED brands, and explicit claims of seamless, bidirectional EHR integration. It also highlights robust data security and compliance (ISO 27001, HDS v2). While Edwards Lifesciences (Tool A's company) is a large, established entity, SignalHF's flexible integration capabilities make it more adaptable for diverse healthcare IT environments.
Innovation
TieBoth tools represent significant innovation in their respective fields. Acumen HPI (Tool A) is a 'first-of-its-kind' technology for real-time, acute hypotension prediction with root cause analysis using machine learning on blood pressure waveforms. SignalHF (Tool B) offers a highly innovative, manufacturer-agnostic approach to predicting heart failure hospitalizations from diverse CIED data, addressing a major interoperability challenge in cardiology.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the availability, scope, or quality of customer support and documentation for either tool. While both companies are expected to provide adequate support, there is no comparative information to determine a winner.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Acumen Hypotension Prediction Index (HPI) Feature Software | SignalHF |
|---|---|---|
| Company | Edwards Lifesciences | Implicity |
| Primary Purpose | Predictive monitoring to detect and alert clinicians to the likelihood of a hypotensive event before it occurs. | Predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices. |
| Target Specialties | Anesthesiology, Critical Care, Emergency Medicine | Cardiology |
| Prediction Target | Likelihood of a hypotensive event | Heart failure hospitalizations |
| Prediction Timeframe | Up to 15 minutes before an event | Within 30 days |
| Data Sources/Compatibility | Invasive (arterial line) and non-invasive (Acumen IQ cuff) monitoring; blood pressure waveforms; integrated into Edwards Lifesciences HemoSphere. | Manufacturer-agnostic compatibility with various CIEDs (pacemakers, ICDs, CRTs); analyzes physiological data, demographics, lead measurements, episodes, and therapies. |
| Key Output/Alerts | Hypotension Prediction Index (HPI) parameter (0-100 score), Smart Alerts and Smart Trend screen, Relationship View screen. | Automatic alerts for care teams based on risk scores, AI-driven alert management. |
Videos
Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index (HPI) Feature Software and SignalHF.